Sanofi India Ltd
SANOFI
Company Profile
Business description
Sanofi India Ltd is a drug manufacturing company that focuses on a range of therapeutic areas, including Diabetes, Cardiology, Consumer Healthcare, Hospital, Central Nervous System, and Anti-Histamines. The company's diabetes presence includes oral anti-diabetic products and insulin. The consumer healthcare area also maintains a nutraceutical portfolio. The company's export markets include Germany, the U.K., Australia, and Russia. The company utilizes strategic partnerships as a component of its growth.
Contact
Saki Vihar Road
Sanofi House, CTS Number 117-B
L&T Business Park
Powai
MumbaiMH400072
INDT: +91 2228032000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
2,174
Stocks News & Analysis
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
stocks
Insights from reporting season: So far, so good
We’ve upgraded our fair value estimate for 29 companies, or 40% of those that have reported thus far.
stocks
3 cheap ASX stocks owned by top rated funds
Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,570.90 | 30.80 | -0.36% |
| CAC 40 | 8,154.51 | 31.93 | 0.39% |
| DAX 40 | 22,287.56 | 27.09 | -0.12% |
| Dow JONES (US) | 43,725.89 | 450.76 | -1.02% |
| FTSE 100 | 8,659.37 | 3.60 | -0.04% |
| HKSE | 23,477.92 | 900.94 | 3.99% |
| NASDAQ | 19,764.02 | 198.34 | -0.99% |
| Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
| NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
| S&P 500 | 6,071.32 | 46.20 | -0.76% |
| S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
| SSE Composite Index | 3,379.11 | 28.33 | 0.85% |